DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Remdesivir |
DMBFZ6L
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Remdesivir. |
1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]
|
[11] |
Metreleptin |
DM1NOEK
|
Moderate |
Increased metabolism of Trabectedin caused by Metreleptin mediated induction of CYP450 enzyme. |
Acute diabete complication [5A2Y]
|
[10] |
Ivosidenib |
DM8S6T7
|
Moderate |
Increased metabolism of Trabectedin caused by Ivosidenib mediated induction of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[10] |
Tagraxofusp |
DM9HQ5U
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Tagraxofusp. |
Acute myeloid leukaemia [2A60]
|
[10] |
Arn-509 |
DMT81LZ
|
Major |
Increased metabolism of Trabectedin caused by Arn-509 mediated induction of CYP450 enzyme. |
Acute myeloid leukaemia [2A60]
|
[10] |
Gilteritinib |
DMTI0ZO
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Gilteritinib. |
Acute myeloid leukaemia [2A60]
|
[10] |
Inotersen |
DMJ93CT
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Inotersen. |
Amyloidosis [5D00]
|
[10] |
Bedaquiline |
DM3906J
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Bedaquiline. |
Antimicrobial drug resistance [MG50-MG52]
|
[12] |
Oxymetholone |
DMFXUT8
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Oxymetholone. |
Aplastic anaemia [3A70]
|
[10] |
Troleandomycin |
DMUZNIG
|
Major |
Decreased metabolism of Trabectedin caused by Troleandomycin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[11] |
Pexidartinib |
DMS2J0Z
|
Major |
Increased risk of hepatotoxicity by the combination of Trabectedin and Pexidartinib. |
Bone/articular cartilage neoplasm [2F7B]
|
[13] |
LY2835219 |
DM93VBZ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and LY2835219. |
Breast cancer [2C60-2C6Y]
|
[10] |
Pralatrexate |
DMAO80I
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Pralatrexate. |
Breast cancer [2C60-2C6Y]
|
[10] |
Tucatinib |
DMBESUA
|
Major |
Decreased metabolism of Trabectedin caused by Tucatinib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[11] |
Palbociclib |
DMD7L94
|
Moderate |
Decreased metabolism of Trabectedin caused by Palbociclib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[10] |
Trastuzumab Emtansine |
DMU1LXS
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Trastuzumab Emtansine. |
Breast cancer [2C60-2C6Y]
|
[10] |
Macitentan |
DMP79A1
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Macitentan. |
Cardiovascular disease [BA00-BE2Z]
|
[10] |
Chenodiol |
DMQ8JIK
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Chenodiol. |
Cholelithiasis [DC11]
|
[10] |
Regorafenib |
DMHSY1I
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Regorafenib. |
Colorectal cancer [2B91]
|
[10] |
Intedanib |
DMSTA36
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Intedanib. |
Colorectal cancer [2B91]
|
[10] |
Pasireotide |
DMHM7JS
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Pasireotide. |
Cushing syndrome [5A70]
|
[10] |
Lumacaftor |
DMCLWDJ
|
Major |
Increased metabolism of Trabectedin caused by Lumacaftor mediated induction of CYP450 enzyme. |
Cystic fibrosis [CA25]
|
[10] |
Ivacaftor |
DMZC1HS
|
Moderate |
Decreased metabolism of Trabectedin caused by Ivacaftor mediated inhibition of CYP450 enzyme. |
Cystic fibrosis [CA25]
|
[10] |
MK-8228 |
DMOB58Q
|
Moderate |
Decreased metabolism of Trabectedin caused by MK-8228 mediated inhibition of CYP450 enzyme. |
Cytomegaloviral disease [1D82]
|
[10] |
Cenobamate |
DM8KLU9
|
Moderate |
Increased metabolism of Trabectedin caused by Cenobamate mediated induction of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[10] |
Stiripentol |
DMMSDOY
|
Moderate |
Decreased metabolism of Trabectedin caused by Stiripentol mediated inhibition of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[10] |
Cannabidiol |
DM0659E
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Cannabidiol. |
Epileptic encephalopathy [8A62]
|
[10] |
Tazemetostat |
DMWP1BH
|
Moderate |
Increased metabolism of Trabectedin caused by Tazemetostat mediated induction of CYP450 enzyme. |
Follicular lymphoma [2A80]
|
[10] |
Boceprevir |
DMBSHMF
|
Major |
Decreased metabolism of Trabectedin caused by Boceprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[11] |
Telaprevir |
DMMRV29
|
Major |
Decreased metabolism of Trabectedin caused by Telaprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[11] |
177Lu-DOTATATE |
DMT8GVU
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and 177Lu-DOTATATE. |
Hepatitis virus infection [1E50-1E51]
|
[10] |
Brentuximab vedotin |
DMWLC57
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Brentuximab vedotin. |
Hodgkin lymphoma [2B30]
|
[14] |
Cobicistat |
DM6L4H2
|
Major |
Decreased metabolism of Trabectedin caused by Cobicistat mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[11] |
Etravirine |
DMGV8QU
|
Moderate |
Increased metabolism of Trabectedin caused by Etravirine mediated induction of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[10] |
Rilpivirine |
DMJ0QOW
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Rilpivirine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[10] |
Mipomersen |
DMGSRN1
|
Major |
Increased risk of hepatotoxicity by the combination of Trabectedin and Mipomersen. |
Hyper-lipoproteinaemia [5C80]
|
[15] |
Teriflunomide |
DMQ2FKJ
|
Major |
Additive myelosuppressive effects by the combination of Trabectedin and Teriflunomide. |
Hyper-lipoproteinaemia [5C80]
|
[16] |
BMS-201038 |
DMQTAGO
|
Major |
Increased risk of hepatotoxicity by the combination of Trabectedin and BMS-201038. |
Hyper-lipoproteinaemia [5C80]
|
[17] |
Tolvaptan |
DMIWFRL
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Tolvaptan. |
Hypo-osmolality/hyponatraemia [5C72]
|
[10] |
Givosiran |
DM5PFIJ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Givosiran. |
Inborn porphyrin/heme metabolism error [5C58]
|
[10] |
Berotralstat |
DMWA2DZ
|
Moderate |
Decreased metabolism of Trabectedin caused by Berotralstat mediated inhibition of CYP450 enzyme. |
Innate/adaptive immunodeficiency [4A00]
|
[10] |
Suvorexant |
DM0E6S3
|
Moderate |
Decreased metabolism of Trabectedin caused by Suvorexant mediated inhibition of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[10] |
Denosumab |
DMNI0KO
|
Moderate |
Additive immunosuppressive effects by the combination of Trabectedin and Denosumab. |
Low bone mass disorder [FB83]
|
[18] |
Crizotinib |
DM4F29C
|
Moderate |
Decreased metabolism of Trabectedin caused by Crizotinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[10] |
Ceritinib |
DMB920Z
|
Major |
Decreased metabolism of Trabectedin caused by Ceritinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[11] |
Lurbinectedin |
DMEFRTZ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Lurbinectedin. |
Lung cancer [2C25]
|
[10] |
PF-06463922 |
DMKM7EW
|
Moderate |
Increased metabolism of Trabectedin caused by PF-06463922 mediated induction of CYP450 enzyme. |
Lung cancer [2C25]
|
[10] |
BIBW 2992 |
DMTKD7Q
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and BIBW 2992. |
Lung cancer [2C25]
|
[10] |
Pralsetinib |
DMWU0I2
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Pralsetinib. |
Lung cancer [2C25]
|
[10] |
Capmatinib |
DMYCXKL
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Capmatinib. |
Lung cancer [2C25]
|
[10] |
Selpercatinib |
DMZR15V
|
Moderate |
Decreased metabolism of Trabectedin caused by Selpercatinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[10] |
Inotuzumab ozogamicin |
DMAC130
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Inotuzumab ozogamicin. |
Malignant haematopoietic neoplasm [2B33]
|
[10] |
Calaspargase pegol |
DMQZBXI
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Calaspargase pegol. |
Malignant haematopoietic neoplasm [2B33]
|
[10] |
Idelalisib |
DM602WT
|
Major |
Decreased metabolism of Trabectedin caused by Idelalisib mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[11] |
IPI-145 |
DMWA24P
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and IPI-145. |
Mature B-cell leukaemia [2A82]
|
[10] |
Blinatumomab |
DMGECIJ
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Blinatumomab. |
Mature B-cell lymphoma [2A85]
|
[10] |
Ponatinib |
DMYGJQO
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Ponatinib. |
Mature B-cell lymphoma [2A85]
|
[10] |
Arry-162 |
DM1P6FR
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Arry-162. |
Melanoma [2C30]
|
[10] |
Vemurafenib |
DM62UG5
|
Moderate |
Increased metabolism of Trabectedin caused by Vemurafenib mediated induction of CYP450 enzyme. |
Melanoma [2C30]
|
[10] |
Ipilimumab |
DMJTIYK
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Ipilimumab. |
Melanoma [2C30]
|
[10] |
Dabrafenib |
DMX6OE3
|
Moderate |
Increased metabolism of Trabectedin caused by Dabrafenib mediated induction of CYP450 enzyme. |
Melanoma [2C30]
|
[10] |
Carfilzomib |
DM48K0X
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Carfilzomib. |
Multiple myeloma [2A83]
|
[10] |
Panobinostat |
DM58WKG
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Panobinostat. |
Multiple myeloma [2A83]
|
[10] |
Elotuzumab |
DMEYHG9
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Elotuzumab. |
Multiple myeloma [2A83]
|
[10] |
Tecfidera |
DM2OVDT
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Tecfidera. |
Multiple sclerosis [8A40]
|
[10] |
Siponimod |
DM2R86O
|
Major |
Additive immunosuppressive effects by the combination of Trabectedin and Siponimod. |
Multiple sclerosis [8A40]
|
[11] |
Fingolimod |
DM5JVAN
|
Major |
Additive immunosuppressive effects by the combination of Trabectedin and Fingolimod. |
Multiple sclerosis [8A40]
|
[19] |
Ocrelizumab |
DMEZ2KH
|
Moderate |
Additive immunosuppressive effects by the combination of Trabectedin and Ocrelizumab. |
Multiple sclerosis [8A40]
|
[20] |
Ozanimod |
DMT6AM2
|
Major |
Additive immunosuppressive effects by the combination of Trabectedin and Ozanimod. |
Multiple sclerosis [8A40]
|
[10] |
Fedratinib |
DM4ZBK6
|
Moderate |
Increased metabolism of Trabectedin caused by Fedratinib mediated induction of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[10] |
Netupitant |
DMEKAYI
|
Moderate |
Decreased metabolism of Trabectedin caused by Netupitant mediated inhibition of CYP450 enzyme. |
Nausea/vomiting [MD90]
|
[10] |
Entrectinib |
DMMPTLH
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Entrectinib. |
Non-small cell lung cancer [2C25]
|
[10] |
Rucaparib |
DM9PVX8
|
Moderate |
Decreased metabolism of Trabectedin caused by Rucaparib mediated inhibition of CYP450 enzyme. |
Ovarian cancer [2C73]
|
[10] |
Abametapir |
DM2RX0I
|
Moderate |
Decreased metabolism of Trabectedin caused by Abametapir mediated inhibition of CYP450 enzyme. |
Pediculosis [1G00]
|
[21] |
Lefamulin |
DME6G97
|
Moderate |
Decreased metabolism of Trabectedin caused by Lefamulin mediated inhibition of CYP450 enzyme. |
Pneumonia [CA40]
|
[22] |
Lonafarnib |
DMGM2Z6
|
Major |
Decreased metabolism of Trabectedin caused by Lonafarnib mediated inhibition of CYP450 enzyme. |
Premature ageing appearance [LD2B]
|
[11] |
ABIRATERONE |
DM8V75C
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and ABIRATERONE. |
Prostate cancer [2C82]
|
[10] |
Enzalutamide |
DMGL19D
|
Major |
Increased metabolism of Trabectedin caused by Enzalutamide mediated induction of CYP450 enzyme. |
Prostate cancer [2C82]
|
[10] |
Ambrisentan |
DMD1QXW
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Ambrisentan. |
Pulmonary hypertension [BB01]
|
[10] |
Axitinib |
DMGVH6N
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Axitinib. |
Renal cell carcinoma [2C90]
|
[10] |
Tocilizumab |
DM7J6OR
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Tocilizumab. |
Rheumatoid arthritis [FA20]
|
[10] |
Canakinumab |
DM8HLO5
|
Moderate |
Additive immunosuppressive effects by the combination of Trabectedin and Canakinumab. |
Rheumatoid arthritis [FA20]
|
[23] |
Rilonacept |
DMGLUQS
|
Moderate |
Additive immunosuppressive effects by the combination of Trabectedin and Rilonacept. |
Rheumatoid arthritis [FA20]
|
[23] |
Golimumab |
DMHZV7X
|
Major |
Additive immunosuppressive effects by the combination of Trabectedin and Golimumab. |
Rheumatoid arthritis [FA20]
|
[24] |
Sarilumab |
DMOGNXY
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Sarilumab. |
Rheumatoid arthritis [FA20]
|
[10] |
Anthrax vaccine |
DM9GSWY
|
Moderate |
Antagonize the effect of Trabectedin when combined with Anthrax vaccine. |
Sepsis [1G40-1G41]
|
[25] |
Voxelotor |
DMCS6M5
|
Moderate |
Decreased metabolism of Trabectedin caused by Voxelotor mediated inhibition of CYP450 enzyme. |
Sickle-cell disorder [3A51]
|
[10] |
Telotristat ethyl |
DMDIYFZ
|
Moderate |
Increased metabolism of Trabectedin caused by Telotristat ethyl mediated induction of CYP450 enzyme. |
Small intestine developmental anomaly [DA90]
|
[10] |
Brilinta |
DMBR01X
|
Moderate |
Decreased metabolism of Trabectedin caused by Brilinta mediated inhibition of CYP450 enzyme. |
Thrombosis [DB61-GB90]
|
[10] |
Lenvatinib |
DMB1IU4
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Lenvatinib. |
Thyroid cancer [2D10]
|
[10] |
Elagolix |
DMB2C0E
|
Moderate |
Increased risk of hepatotoxicity by the combination of Trabectedin and Elagolix. |
Uterine fibroid [2E86]
|
[10] |
----------- |
|
|
|
|
|